Asaan Pharma announces the latest clinical advances in Bcl-2 inhibitor APG-2575

Today, Asaan Pharma announced its latest clinical advances in the development of a new class 1 drug, Bcl-2 inhibitor APG-2575.
specifics are as follows: Worldwide, 9 clinical studies are under way, with a total of more than 100 patients receiving APG-2575 in doses from 20mg to 1200mg, involving diseases such as chronic lymphocytic leukemia (CLL), fiery lymphoma (FL), clerical lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), acute myeloid leukemia (AML), high leukemia (HCL), etc. . . More than 30 patients have been included in clinical studies for relapsed/refractic CLLs, and preliminary clinical results show that the objective remission rate (ORR) in assessable patients reached 70% . . . in terms of safety: 1. No maximum to-dosoded dose (MTD), no restricted toxicity dose (DLT) 2. No laboratory or clinical tumor dissolution syndrome (TLS) was observed 3. Most drug-related adverse reactions are level 1 or 2 4. The rate of reduction of neutral granulocytes and plate plateplate reduction is very low. A total of three FDA orphan drug certification, the adaptive disorders are CLL, MM, Fahrenheit globulinemia (WM) APG-2575 is a new oral Bcl-2 selective small molecule inhibitor independently developed by Asason Pharmaceuticals, through selective inhibition of Bcl-2 protein to restore the tumor cell program death mechanism (cell apoptosis), so as to achieve the purpose of treating blood and solid tumors.
, the drug is the first locally developed Bcl-2 selective inhibitor to enter the clinical phase in China.
as a single drug, APG-2575 has strong anti-tumor activity for Bcl-2-dependent tumor cells and exhibits broader anti-tumor activity in combination with other anticancer drugs.
APG-2575 has been licensed for several clinical trials in the United States, China, Australia and Europe and is advancing clinical development, including multiple blood tumor adaptations, globally.
。